Past, present and future of alteplase for acute ischemic stroke

Quinn, T.J. , Dawson, J. and Lees, K.R. (2008) Past, present and future of alteplase for acute ischemic stroke. Expert Review of Neurotherapeutics, 8(2), pp. 181-192. (doi: 10.1586/14737175.8.2.181)

Full text not currently available from Enlighten.


Thrombolysis for acute ischemic stroke has revolutionized stroke medicine. The only agent licensed for clinical use is the tissue plasminogen activator alteplase. A considerable evidence base confirms clinical and economic efficacy of alteplase use in selected patients. Meta-analyses suggest that for every 100 patients treated within 3 h, 32 will achieve a better outcome, while only three will suffer an important bleeding complication. These good-quality trial data are complemented by over a decade's worth of clinical experience that confirms the efficacy and safety of alteplase. Studies designed to enhance efficacy are ongoing. Unfortunately, current rates of thrombolysis remain disappointingly low. Thus, while novel approaches to lysis administration are welcome, strategies to improve lay-public and medical awareness of acute stroke and potential treatments are also required

Item Type:Articles
Glasgow Author(s) Enlighten ID:Lees, Professor Kennedy and Dawson, Professor Jesse and Quinn, Dr Terry
Authors: Quinn, T.J., Dawson, J., and Lees, K.R.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Expert Review of Neurotherapeutics
Journal Abbr.:Expert Rev. Neurother.
ISSN (Online):1744-8360

University Staff: Request a correction | Enlighten Editors: Update this record